Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. (Q40468558)
Jump to navigation
Jump to search
scientific article published on 15 March 2006
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. |
scientific article published on 15 March 2006 |
Statements
1 reference
Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. (English)
1 reference
Thomas P Monath
1 reference
Farshad Guirakhoo
1 reference
Scott Kitchener
1 reference
Dennis Morrison
1 reference
Remi Forrat
1 reference
Karen McCarthy
1 reference
Richard Nichols
1 reference
Sutee Yoksan
1 reference
Xiaochu Duan
1 reference
Thomas H Ermak
1 reference
Niranjan Kanesa-Thasan
1 reference
Philip Bedford
1 reference
Jean Lang
1 reference
Marie-Jose Quentin-Millet
1 reference
15 March 2006
1 reference
1 reference
Identifiers
1 reference